<b>Conclusions</b>: Diabetes-specific enteral formula did not improve mean glucose level or insulin requirement in critically ill patients with T2DM, although it was associated with better maintenance of the target glycemic range and lower product-related costs. The gene discussed is INS; the disease is diabetes mellitus.